Sucralfate Oral Suspension Recalled Due to Microbial Contamination
VistaPharm is recalling Sucralfate Oral Suspension, 1g/10mL because of Bacillus cereus contamination.
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
FDA announced on Sept. 22, 2023 that VistaPharma is voluntarily recalling one lot of Sucralfate Oral Suspension, 1g/10mL, because of contamination of the product by Bacillus cereus. The product, which is used as an antiulcer therapeutic and distributed nationwide, is packaged in a 16 oz (414 mL) polyethylene terephthalate bottle with NDC 66689-305-16. The recalled lot is number 810300 with an expiration date of Oct. 31, 2023.
Microbial contamination of the oral suspension may result in life-threatening infections, such as endocarditis and necrotizing soft tissue infections, according to a press release. As of the time of the press release, the company had not received any reports of adverse events. Adverse events may be reported to FDA via the agency’s MedWatch Adverse Event Reporting program.
The recall is being undertaken by a contractor, Inman, which is notifying distributors and arranging for the return of recalled product.
Source: FDA
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.
